Monthly Prescribing Reference: Non-Vitamin K Antagonist Oral Anticoagulants vs Warfarin in NVAF Patients Findings may help with decision-making in this high-risk patient population. Compared with warfarin, non-vitamin K antagonist oral anticoagulants (NOACs) are associated with lower rates of stroke ... It’s reasonable, and perhaps preferable, to switch frail older patients with atrial fibrillation (AF) from a vitamin K antagonist like warfarin to a direct oral anticoagulant (DOAC) for stroke ...

Understanding the Context

Patients with thrombotic antiphospholipid syndrome are better treated with a vitamin K antagonist, such as warfarin, rather than a direct oral anticoagulant (DOAC), a new systematic review and ... Healio: Non-vitamin K antagonist oral anticoagulants beneficial for patients with AF, cancer Please provide your email address to receive an email when new articles are posted on . In patients with atrial fibrillation and cancer, non-vitamin K antagonist oral anticoagulants outperformed ... Healio: Diabetes complications less likely in non-vitamin K antagonist oral anticoagulant users Please provide your email address to receive an email when new articles are posted on .

Key Insights

Adults with atrial fibrillation and diabetes who received non-vitamin K antagonist oral anticoagulants had a ... Warfarin is a derivative of coumarin which interferes with the cyclic interconversion of vitamin K and its epoxide. Vitamin K is an important factor in the normal function of the coagulation system. Nasdaq: Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology Congress Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology Congress